Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum Toxin Type A for Persistent Idiopathic Facial Pain
NCT03462290Phase 2Completed
- Sponsor
- Norwegian University of Science and Technology
- Start
- May 2018
- Primary completion
- Nov 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of botulinum toxin type A in persistent idiopathic facial pain (PIFP), sponsored by Norwegian University of Science and Technology. Started May 2018; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
persistent idiopathic facial pain (PIFP)
Beyond the preview
Go deeper on NCT03462290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03462290.